comminuted fracture union of tibia and femural shaft.
Conditions
Interventions
Intervention group: daily 20 micro grams of triparatide (Sinopar) subcutaneously for six months.
Sponsors
Karaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Having comminuted fractured tibia and femural shaft Obtaining informed consent to participate in this study Being between 18-45 years old Not having osteoporosis that has been confirmed in the radiographies Not being allergic to triparatide If a person has previously used bisphosphonates, at least three months should pass after stopping their use, and then start triparatide. Not having a serious underlying disease such as uncontrolled diabetes, heart failure, kidney failure, etc. Not having Paget's disease, hypercalcemia for any reason, hyperparathyroidism No history of osteosarcoma
Exclusion criteria
Exclusion criteria: Under 18 and over 45 years old Allergy to triparatide Having a serious underlying disease such as uncontrolled diabetes, heart failure, kidney failure, etc. Having Paget's disease, hypercalcemia for any reason, hyperparathyroidism Having a history of osteosarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Union of comminuted fracture of tibia and femural shaft fracture. Timepoint: Every month after prescribing the drug for up to six months. Method of measurement: Clinical sign and symptoms and radiographic signs. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamed Azadi
Karaj University of Medical Sciences
Outcome results
None listed